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Asubstantialbodyofevidencesuggeststhatanabnormalintrauterinemilieuelicitedbymaternalmetabolicdisturbancesasdiverse
as undernutrition, placental insuﬃciency, diabetes or obesity, may program susceptibility in the fetus to later develop chronic
degenerative diseases, such as obesity, hypertension, cardiovascular diseases and diabetes. This paper examines the developmental
programming of glucose intolerance/diabetes by disturbed intrauterine metabolic condition experimentally obtained in various
rodent models of maternal protein restriction, caloric restriction, overnutrition or diabetes, with a focus on the alteration of
the developing beta-cell mass. In most of the cases, whatever the type of initial maternal metabolic stress, the beta-cell adaptive
growth which normally occurs during gestation, does not take place in the pregnant oﬀspring and this results in the development
of gestational diabetes. Therefore gestational diabetes turns to be the ultimate insult targeting the oﬀspring beta-cell mass and
propagates diabetes risk to the next generation again. The aetiology and the transmission of spontaneous diabetes as encountered
in the GK/Par rat model of type 2 diabetes, are discussed in such a perspective. This review also discusses the non-genomic
mechanisms involved in the installation of the programmed eﬀect as well as in its intergenerational transmission.
1. PerinatalRisk Factors for
DiabetesinLaterLife
Type 2 diabetes mellitus (T2D) is a complex polygenic
disease that often manifests years before eventual clinical
diagnosis [1] .T 2 Dd e v e l o p sa sar e s u l to faf a i l u r et o
adequately increase beta-cell function and mass to meet
the demands of prevailing insulin resistance [2]. The
contribution of beta-cell failure to the pathophysiology of
T2D is supported by islet pathology that reveals a beta-
cell deﬁcit of approximately 50 and 65% in individuals
with impaired fasting glucose and T2D, respectively [3].
Consistent with these observations, most genes linked to
T2D by genome-wide association scans have been shown
to inﬂuence some aspects of beta-cell biology, such as
regulation of beta-cell secretory function and development
and growth of beta-cell mass [4]. It has long been recognized
that nutrient availability during fetal and early postnatal life
is an important determinant of adult health [5].
There are strong arguments showing that T2D is more
prevalent among subjects that were in utero exposed to
maternal diabetes (IUED). The role of maternal inheritance
in T2D has been reported in a majority of epidemiological
studies [6, 7]. To determine the role of the intrauterine
diabetic environment per se, the prevalence of diabetes
was compared in Pima nuclear families in which at least
one sibling was born before and one after the mother was
diagnosed with T2D. Oﬀspring born after their mother
displayed diabetes had a fourfold higher risk of diabetes and
a higher body mass index (BMI) than their full siblings born
before their mother developed diabetes [8]. These ﬁndings
indicatethatintrauterineexposuretoadiabeticenvironment
increases risk of obesity and T2D beyond that attributable
to genetic factors, at least in Pima Indians. To circumvent
the confounding eﬀect of genes linked to early onset T2D
and transmitted by the pregnant T2D mother, the eﬀect
of fetal exposure to T1D was evaluated in adult oﬀspring
lacking T1D immunological markers. A 33% prevalence of2 Experimental Diabetes Research
IGT was reported in oﬀspring of T1D mothers compared
with none in oﬀspring of T1D fathers (control group) [9].
Altogether, these ﬁndings suggest that fetal exposure to
maternaldiabetesisindeedassociatedwithabnormalglucose
homeostasis in oﬀspring and may participate in the excess of
maternal transmission in T2D. In adult Pima Indians with
normal glucose tolerance and who had been exposed to an
intrauterine diabetic environment, acute insulin response
to i.v. glucose was found reduced in those oﬀspring whose
mother was diabetic before pregnancy while it remained
normal in those whose mother developed diabetes after
pregnancy, [10]. Body fat and insulin sensitivity (euglycemic
hyperinsulinemic clamp) were similar in the two groups of
subjects [10]. In the same study, acute insulin response was
found reduced in oﬀspring of parents (mother or father)
with early onset of T2D [10], suggesting that gene(s) linked
toearly-onsetdiabetesis(are)associatedwithreducedinsulin
secretoryresponsetoglucose[11].OﬀspringofT1Dmothers
hadreducedinsulinsecretion,morepronouncedinIGTsub-
jects, but similar fat mass and insulin action compared with
oﬀspring of T1D fathers [9]. Also in nondiabetic oﬀspring of
mothers with young-onset T2D (diagnosed under age 50),
beta-cell function (early insulin release after oral glucose)
was found decreased as compared to that of oﬀspring
of fathers with young-onset T2D [12]. Therefore, human
studies suggest that insulin secretion defect participates in
the abnormal glucose tolerance observed in adult oﬀspring
exposed to maternal diabetes during fetal life. Importantly,
they showed that insulin secretion may be reduced even in
normal glucose-tolerant oﬀspring. Nevertheless, in children
and adolescent oﬀspring, insulin resistance involvement was
suggested and may be related, at least in part, to their higher
body weight.
Beside studies in IUED populations, prenatal nutrient
insuﬃciency resulting in low birth weight is also associated
with increased risk for development of obesity, cardiovas-
cular disease, and T2D [13–15]. The association between
low birth weight and development of T2D was ﬁrst reported
in classic studies by Hales et al. [15] that demonstrated a
severalfold increase in the incidence of glucose intolerance
and T2D in adult males that were born small compared
with those who were born at a normal birth weight.
These seminal observations since have been consistently
reproduced by numerous investigators worldwide [16].
Although epidemiological evidence linking low birth weight
with increased susceptibility to T2DM is strong [16], the
molecular and physiological mechanisms underlying this
association are still under investigation [17]. It has long been
appreciated that low birth weight is associated with adult
insulin resistance, which can contribute to the increased risk
in development of T2D [18]. However, susceptibility to T2D
in low-birth-weight individuals has also been hypothesized
to be attributed to inadequate beta-cell mass formation [15].
Because it is not possible to measure beta-cell mass in vivo,
thishypothesiscannotyetbetesteddirectlyinhumans.How-
ever, evidence suggests that inadequate beta-cell formation
in utero may underlie subsequent susceptibility for T2D.
First, the fetal period is critical for endocrine pancreatic
development in rodents and humans [19]. Second, clinical
data show that children and adults with low birth weight
demonstrate impaired beta-cell function compared with
their normal birth-weight counterparts [20, 21]a n dh u m a n
fetuses with severe growth retardation, have a reduction in
pancreatic endocrine cell mass [22].
In this paper, we discuss the evidence for beta-cell dys-
function in IUED (in utero exposed to maternal diabetes),
IUEO (in utero exposed to maternal overnutrition) and
IUGR (in utero growth restriction) animal models, focusing
on the strengths and limits of each, in order to deﬁne
critical periods and types of alterations that can lead to
impaired beta-cell function. We also discuss several potential
mechanisms dissected in relevant animal models that begin
to explain this outcome.
2. CompromisedIntrauterineEnvironmentand
Risk for DiabetesinLaterLife
Thanks to abundant studies mostly in rodents in which
the foetal environment can be manipulated, a substantial
body of data now addresses the mechanisms involved in
the developmental programming of glucose intolerance and
T2D.
IUED Models. In rat, maternal diabetes may be induced
experimentally by streptozotocin (STZ) injection that selec-
tively destroys beta-cells. Mild or severe diabetes ensue
depending on the dose used. At birth, the progeny of mild
diabetic mothers had normal weight or slight macrosomia
and an enhanced percentage of pancreatic endocrine tissue
due to hyperplasia and hypertrophy of the islet cells [24,
25], leading to a higher beta-cell mass that was hyper-
vascularized [26]. The pancreatic insulin content and insulin
secretion were raised in these fetuses [27]. On the other
hand, fetuses from severe diabetic dams were small at birth
and had decreased pancreatic weight [28]. Their beta-cells
were almost degranulated, leading to low pancreatic insulin
content and low plasma insulin [27]. Similar endocrine
pancreas/beta-cell alterations with low beta-cell mass have
been reported in fetuses from spontaneous diabetic BB rats
[29] or spontaneous diabetic GK rats [30, 31]. The long-
term consequences have been evaluated in the progeny of
these models. Impaired glucose tolerance was observed in
the oﬀspring of mild STZ diabetic rats due to lower insulin
secretion in response to glucose, while insulin resistance was
reported in the oﬀspring of the severe STZ diabetic mothers
[32–34]. Glucose tolerance was also impaired in oﬀspring
of normal mothers receiving glucose infusion during late
gestation, and it was associated with decreased glucose-
induced insulin secretion [24, 35–37].
The greatest diﬃculty in most animal models of diabetic
pregnancy has been the attainment of a stable degree of
mild hyperglycemia during gestation. Though useful, most
techniques used to achieve models of diabetes in pregnancy
have some drawbacks. Maternal glucose infusions limited
to the last trimester of pregnancy result in hyperglycemia
and hyperinsulinemia and do not mimic the relative insulin
deﬁciency of gestational diabetes [38]. The multiple lipidExperimental Diabetes Research 3
and protein abnormalities associated with diabetes may be
as important in the induction of fetal abnormalities as
hyperglycemia, but they are not replicated by the maternal
glucose infusion model. A concern of studies using STZ
during pregnancy is the possibility that the toxin might cross
the placenta and be directly harmful to the fetal pancreas
and other fetal tissues, and thus make any analysis of the
long-term eﬀects of hyperglycemia in utero diﬃcult [39].
The problem may be circumvented by giving STZ to female
neonates who will later become pregnant: this will result in
moderate gestational hyperglycemia [40]. Finally it must be
recognized that none of the previously mentioned models
will serve directly as a model of human gestational diabetes.
An ideal animal model to test the isolated impact
of diabetic pregnancy would enter the pregnancy in a
euglycemic state, become exposed to hyperglycaemic during
whole pregnancy, and return postpartum to normoglycemic
environment. Such a model also would allow study of the
long-term eﬀects of diabetes independent of any genetic
inﬂuence. It was recently proposed that the pregnant GK rat
being transferred normal Wistar (W) rat embryo represents
a more relevant paradigm in such a perspective [41]. Using
the GK/Par rat (Figure 1)w eh a v et r a n s f e r r e dWr a to o c y t e s
to diabetic GK/Par females, and at their birth the W
neonates were suckled by nondiabetic W foster mothers.
Under these unique conditions, we have found that maternal
diabetes negatively imprints the growth of a genetically
normal (Wistar) beta-cell mass in a way as the insult is still
present later at adult age as a decreased beta-cell population
[42, 43]. Not only maternal diabetes but also intrauterine
undernutrition induced by several means such as protein
(IUPR) or calorie (IUCR) restriction, or alteration in the
availability of the nutrients by uterine/placental insuﬃciency
(UPI) induced by uterine artery ligation, alter early islet
development and provoke lasting consequences in rodents.
IUCR Models. Global restrictions (to 40–50% of normal
intake) (IUCR) in the last week of rat pregnancy results
in low birth weight oﬀspring with decreased beta-cell
mass. Although these animals can regain their body and
pancreatic weights upon normal postnatal feeding, they still
demonstrate a reduced beta-cell mass and insulin content
in adulthood [44, 45]. Extending this level of nutrient
restriction during suckling results in a permanent reduction
of beta-cell mass [46, 47] and subsequent age-dependent loss
of glucose tolerance in the oﬀspring [48]. Underfeeding the
rat mothers during the ﬁrst two weeks of gestation exerts no
adverseeﬀectuponinsulinsecretionandinsulinactioninthe
adult male oﬀspring [49].
IUPR Models. The maternal protein restriction (5–8% as
compared to 20% in normal diet) (IUPR) model has been
oneofthemostextensivelystudiedmodels.Thelow-protein-
fed mothers give birth to growth-restricted oﬀspring [50–
54], and when suckled by their mothers maintained on
the same low-protein fed, they remain permanently growth
restricted, despite being weaned on a normal diet [53].
Reduced placental weight and endocrine and metabolic
abnormalities are also observed [50, 55, 56]. Despite young
oﬀspring of low-protein-fed dams demonstrating improved
glucose tolerance [56, 57], the male oﬀspring undergo an
age-dependent loss in glucose tolerance, such that by 17
months of age they develop T2D and insulin resistance
[58]. Female oﬀspring only develop hyperinsulinemia and
impaired glucose tolerance at a much later age (21 months)
[54]. Studies in this model have also demonstrated reduc-
tionsinbeta-cellmass[51],skeletalmusclemass[53],central
adipose deposit weights [57, 59], and insulin signalling
defects in muscle, adipocytes, and liver [59–61]. This IUPR
model has also been associated with the development of
hypertension with the kidney and the rennin-angiotensin
system as playing a role [62].
UPI Models. Fetal growth retardation may also result from
experimental uteroplacental insuﬃciency (UPI). Fetal UPI
rats have decreased levels of glucose, insulin, IGF1, amino
acids, and oxygen [63–65]. UPI oﬀspring develop diabetes
in later life [66, 67] with a phenotype that is similar to that
observedinT2Dhumanswithalterationsininsulinsecretion
and action and a failure of beta-cell function and growth
[68, 69].
IUEO Models. There are several reports on the consequences
ofahigh-fatdiet(duringgestationonlyorbothgestationand
lactation) on the adult progeny. High-fat diet consumption
by female rats malprograms the male oﬀspring for glucose
intolerance and increased body weight in adulthood [70].
Some of the observed consequences include reduced whole-
bodyinsulinsensitivity,impairedornormalinsulinsecretion
and changes in the structure of pancreas [71–74], defective
mesenteric artery endothelial function [75], hypertension
[76, 77], alterations in renal functions [78], increased body
adiposity [72, 76], deranged blood lipid proﬁle [71, 76,
78], hyperleptinemia [72], and proatherogenic lesions [79].
There are not many reports on fetal islet adaptations due
to a high-fat dietary modiﬁcation in the dam. Cerf et al.
[80] demonstrated that feeding rat female with a high-fat
diet throughout gestation resulted in signiﬁcant decreases
in beta-cell volume and number resulting in hyperglycemia
in 1-day-old newborn rat pups without changes in serum
insulin concentrations. However, the report of fetal hyperin-
sulinemia in the high-fat term rat fetus [70] is not consistent
with this ﬁnding.
Maternal obesity in mice, in the absence of diabetes,
can also impair glucose tolerance in genetically normal
oﬀspring. This was shown using mothers carrying the
Agouti (Ay) mutation on a C57BL/6 background. On this
background, the Ay mutation produces marked obesity
without diabetes. At adult age while maintained on normal
diet,geneticallynormal,adultfemaleoﬀspringofAy-positive
mothersexhibitedreducedglucose-inducedinsulinsecretion
in vivo [81].
Also male mice whose mothers consumed a high-fat
diet were heavier, glucose intolerant, and insulin resis-
tant and produced second-generation oﬀspring who were
insulin resistant, although not obese [82]. Whether this is4 Experimental Diabetes Research
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Figure 1: From the nondiabetic Wistar rat to the spontaneously diabetic GK (Goto-Kakizaki) rat. The inbred GK rat line (Wistar strain)
was produced by Goto et al. at Tohoku University, Senda¨ ı, Japan, by selective breeding of normal Wistar rats over many generations using
glucosetolerancevalue(andnotbasalglucosevalueonly)asadiscriminantphenotype[23].OnlyWratsselectedattheupperlimitofnormal
distribution for glucose tolerance were used. The diabetic state (basal hyperglycemia) was reported to become stable after the 30 generations
of selective crosses in the original Japanese colony. Here is illustrated the distribution of the sum of blood glucose values (
 
blood glucose)
during standardised oral glucose tolerance tests (OGTTs) performed in original parent Wistar rats, in rats from generations F1 to F35 in the
original Japanese colony and in rats from generations F35 to F120 bred under our conditions in Paris from 1989 until now (subline GK/Par).
In the inbred GK/Par rat line, all rats are nonoverweight, nonketotic, and display moderate fasting hyperglycemia with strong postprandial
glucose intolerance. No attenuation, nor aggravation, of the diabetic phenotype overtime (more than 20 years and 80 generations) was
registered in the GK/Par line.
a consequence of paternal in utero exposure or their adult
sequelae of obesity and diabetes is unclear. It was recently
reported that chronic high-fat diet consumption in father
rats induced increased body weight, adiposity, impaired
glucose tolerance, and insulin sensitivity in their oﬀspring
[83]. Relative to controls, their female oﬀspring had an early
onset of impaired insulin secretion and glucose tolerance
that worsened with time and normal adiposity. Among
the diﬀerentially expressed islet genes, hypomethylation of
the Il13ra2 gene was demonstrated. This is a proof ofExperimental Diabetes Research 5
IUED IUCR IUEO UPI IUPR
mF0
mF1
mF2 mF2
mF3 mF3
mF0 mF0 mF0 mF0
fF1 fF1 fF1 fF1
fF2
fF3 fF3 
fF4 fF4 
fF1
I
n
s
u
l
t
d
u
r
i
n
g
p
r
e
g
n
a
n
c
y
(
I
G
T
/
d
i
a
b
e
t
e
s
)
I
n
s
u
l
t
d
u
r
i
n
g
p
r
e
g
n
a
n
c
y
(
I
G
T
/
d
i
a
b
e
t
e
s
)
I
n
s
u
l
t
d
u
r
i
n
g
p
r
e
g
n
a
n
c
y
(
I
G
T
/
d
i
a
b
e
t
e
s
)
(1) (2)
Figure 2: Mechanisms for the installation and intergenerational transmission of programmed beta cell mass (BCM) disruption in response
to compromised intrauterine environment. The initial insults in F0 mother (mF0) impact the developing BCM of the fetuses (fF1). Diverse
initial insults (IUED, IUCR, IUPR, UPI, IUEO), alone or in combination, give rise to the same programmed BCM outcome. Altered
BCM phenotype in F1 females does not allow normal BCM adaptation during pregnancy and IGT/diabetes ensues (gestational diabetes).
Gestational diabetes in the F1 pregnant mother (mF1) acting as an ultimate insult impacts the developing BCM of the F2 fetuses (fF2).
Altered BCM phenotype in F2 females does not allow normal BCM adaptation during pregnancy and IGT/diabetes ensues (gestational
diabetes). Gestational diabetes in the F2 pregnant mother (mF2) acting as an ultimate insult impacts the developing BCM of the F3 fetuses
(fF3), therefore perpetuating similar BCM programming across generations. There are at least two potential scenarii for the transmission
of BCM programming to subsequent generations: (1) the insult as seen in the F1 mother (IGT/diabetes insult during pregnancy) directly
impairs BCM development, but BCM malprogramming is not necessarily irreversible. However, as the environmental insult (gestational
diabetes) persists across generations, it recreates the same gestational phenotype in each subsequent generation (panel 1 in Figure 2); (2)
the insult as seen in the F1 mother permanently aﬀects BCM and results in the perpetuation of BCM malprogramming in the subsequent
generations, in the absence of a further gestational insult (panel 2 in Figure 2). M: mother; f: fetus; F1: ﬁrst-generation animals procreated by
parent(F0)femalessubmittedtoexperimentallydisturbedmetabolismduringtheirpregnancy;F2:second-generationanimalsprocreatedby
F1 females exposed to intrauterine-disturbed metabolism; IUED: in utero exposed to maternal diabetes; IUCR: in utero exposed to maternal
calorie restriction; IUPR: in utero exposed to maternal protein restriction; UPI: uteroplacental insuﬃciency; IUEO: in utero exposed to
maternal overnutrition or obesity.
concept that paternal high-fat-diet exposure programs beta-
cell dysfunction in rat F1 female oﬀspring. This is the
ﬁrst report in mammals of nongenetic, intergenerational
transmission of metabolic sequelae of a high-fat diet from
father to oﬀspring [83].
Among the many types of maternal metabolic stress
used to produce IUGR, hypercholesterolemia combined to
high fat diet was recently added since feeding LDL receptor
null (LDLR−/−) mice with a high-fat resulted in litters
with signiﬁcant growth retardation. The LDLR−/− high-fat
diet oﬀspring developed signiﬁcantly larger atherosclerotic
lesions by 90 days compared with chow diet oﬀspring [84].
Importantly, maternal hypoaminoacidemia proved to be an
important antecedent in this hypercholesterolemic IUGR
mouse[84]asinaprotein-deﬁcientIUGRmousemodel[84]
and an IUED rat model [85]. It may be an important link
in the mechanisms that contribute to adult-onset glucose
intolerance, obesity, and atherosclerosis. In this study beta-
cell mass was not investigated.
Tosumup,itturnstobemanifestthat,despitediﬀerences
in the type, timing, and duration of intrauterine insult,
most animal models of IUED, IUCR, IUPR, or IUEO have
outcomes of impaired glucose tolerance or T2D (Figure 2).
3. VariousEarly-LifeStressors,the SameTarget:
The DevelopingBeta-CellMass
As abundantly illustrated in animal models, many early-life
stressors such as maternal hyperglycaemia, undernutrition,
overnutrition, hypercholesterolemia, corticosteroid therapy,
uteroplacental insuﬃciency, or hypoxia trigger a beta-cell
mass adaptive response in the fetus (Figure 2, Table 1).6 Experimental Diabetes Research
Table 1: Beta-cell (BC) mass characteristics in rodent models of compromised intrauterine environment.
Rodent models
BC phenotype
fetal neonatal/suckling adult
IUED, mild STZD (F1) Increased BC mass, high BC
proliferation [24–27]
Increased BC mass, high
BC proliferation, high islet
vascularisation [24, 25]
Normal BC mass, low
GSIS, low GT [24]
F2 issued from mild STZD F1 NR NR Low GSIS, low GT
[26, 32]
IUED, severe STZD (F1) low BC mass [27, 28]N R
Increased BC mass,
high GSIS, low GT
[32–34, 39]
IUED, GI (F1) Slightly increased BC mass,
high BC proliferation [35] NR Low GSIS, low GT
[24, 35–38]
F2 issued from GI F1 NR NR Low GSIS, low GT
[35]
IUED, GK/Par Low BC mass, low BC
neogenesis [30, 31, 42, 86, 87]
L o wB Cm a s s ,l o wB C
neogenesis [88]
L o wB Cm a s s ,l o wB C
proliferation, low
GSIS [23, 88, 89]
Severe IUCR (F1)
Increased BC mass, high BC
neogenesis, high BC
proliferation [46, 90–92]
NR
L o wB Cm a s s ,l o wB C
proliferation, low
GSIS [46]
IUCR (F1) Low BC mass, low BC
neogenesis [44, 45, 93] Low BC mass [47] Low BC mass, low
GSIS, low GT [44–49]
F2 issued from IUCR F1 Low BC mass, low BC
neogenesis [94] NR Low GSIS, low GT
[32]
IUPR (F1)
Low BC mass, low BC
proliferation, low islet
vascularization [50, 51, 93, 95]
Low BC mass [93]
Low BC mass, low
GSIS, low GT
[51, 53, 54, 56–
62, 96–98]
F2 issued from IUPR F1 Low BC mass [26]N R N o r m a l G T [ 99]
UPI (F1)
Normal BC mass, low BC
proliferation, low islet
vascularization [63–65]
Normal BC mass [65–67]
Low BC mass, low
GSIS, low GT
[66, 67, 100, 101]
F2 issued from UPI F1 NR NR
L o wB Cm a s s ,l o wB C
proliferation, low
GSIS, low GT [32]
IUEO (F1) NR Slightly reduced BC mass
[80]
Normal or decreased
GSIS, low GT
[70–76, 81–84]
F2 issued from IUEO F1 NR NR Normal GT [82]
NR: not reported in the literature to the author’s knowledge; GSIS: glucose-stimulated insulin secretion; GT: glucose tolerance; STZD: diabetes obtained after
streptozotocin administration to adult females several days before mating or during pregnancy; GI: continuous glucose infusion in unrestrained normal
pregnant rat during the last week of pregnancy; F1: ﬁrst-generation animals procreated by parent (F0) females submitted to experimentally disturbed
metabolism during their pregnancy; F2: second-generation animals procreated by F1 females exposed to intrauterine disturbed metabolism; IUED: in
utero exposed to maternal diabetes; IUCR: in utero exposed to maternal calorie restriction; IUPR: in utero exposed to maternal protein restriction; UPI:
uteroplacental insuﬃciency; IUEO: in utero exposed to maternal overnutrition or obesity.
3.1. Critical Windows for Adaptive Response to Early-Life
Stressors. The development of the endocrine pancreas starts
from a pool of common precursor cells that become
progressively committed to the endocrine lineage under the
control of a hierarchical network of transcription factors.
During late fetal and early postnatal life, the beta-cell
mass is determined by the recruitment of undiﬀerentiated
precursors, as well as the replication and apoptosis rates of
thebetacells.Obviously,anydisturbanceoftheenvironment
of the endocrine cells at a speciﬁc developmental time-point,
as it occurs in a perturbed intrauterine milieu, may modify
the balance of controlling factors, thereby contributing to
an adaptive beta-cell growth response which is metabolically
appropriate on the short term. However, this adaptive
response may turn to be detrimental if maintained on the
long term, as it may foster beta-cell failure and diabetes later
in life. We are largely ignorant of when programming may be
initiated during development.
Preimplantatio. An early onset for programming was indi-
cated, as maternal low-protein diet during only the
preimplantation period of rat development (0–4 days afterExperimental Diabetes Research 7
mating), before return to control diet for the remainder
of the gestation, induced blastocyst abnormalities, and pro-
gramming of postnatal growth rate and hypertension [102].
Morespeciﬁcallyitwasshownthatpreimplantationembryos
c o l l e c t e df r o md a m sa f t e r0 – 4d a y so fm a t e r n a ll o w - p r o t e i n
diet displayed signiﬁcantly reduced cell numbers, within
the inner cell mass and trophectoderm lineages, apparently
induced by a slower rate of cellular proliferation. The low-
proteindietsigniﬁcantlyreducedinsulinandessentialamino
acid levels and increased glucose levels within maternal
serum by day 4 of development. These data indicate that
the mildly hyperglycemic and amino-acid-depleted maternal
environment generated by undernutrition may act as an
early mechanism of programming and initiate conditions of
“metabolic stress,” restricting early embryonic proliferation
and the generation of appropriately sized stem-cell lineages.
In chemically or genetically obtained rat diabetes models in
which maternal serum insulin depletion and hyperglycemia
are induced, proliferation of inner cell mass or total cell
numbers within blastocysts is inhibited [103, 104]. There-
fore, the preimplantation embryo is particularly sensitive
to metabolic modiﬁcations that may have programming
consequences [105, 106], and one possibility is that it is the
preimplantation embryo itself that is programmed.
Postimplantation. Embryo transfer experiments may also
help to dissociate the impact of the maternal environment
in early (preimplantation) versus late gestation (postimplan-
tation). We recently found that embryos (blastocysts) from
a nondiabetic Wistar strain placed into a diabetic GK/Par
uterus develop a reduced beta-cell mass which remains low
on the long term [42]. Data with rat models of prenatal
undernutrition [95] also illustrate that low-energy and low-
protein diets that reduce the development of the beta-cell
mass in both cases act at diﬀerent critical time windows. The
beta-cellmassisdeﬁcientinthelow-energypancreasbecause
this diet reduces neogenesis, probably because of high gluco-
corticoid levels, rather than by impairing vascularisation and
proliferation. Early gestation is thus a very sensitive period in
this model. By contrast, pancreatic alterations take place at a
later fetal stage in the low-protein model, and the beta-cell
mass is deﬁcient in this case because this diet reduces beta-
cell vascularisation and proliferation without altering beta-
cell diﬀerentiation [95].
Postnatal versus Prenata. Further support for the crucial
impact of prenatal nutritional environment is the recent
report that prenatal nutrient restriction in both male and
female rats led to an inappropriate postnatal beta-cell mass
formation attributed to a decrease in the rate of beta-cell
replication and beta-cell neogenesis [93]. In contrast, male
and female rats exposed to postnatal nutrient restriction
alone (with normal prenatal nutrient exposure) were char-
acterized by decreased pancreatic and body weights, but a
weight-adjusted beta-cell mass higher compared to control
animals [93]. Another illustration is oﬀered by observations
in normal rat pups reared artiﬁcially on a high-carbohydrate
milk formula [107]: such alteration of nutrition, during the
sucklingperiodonly,inducedpersistentadaptationofenergy
metabolism in adulthood (obesity, glucose intolerance, and
impaired insulin secretion).
3.2. Molecular Mechanisms Mediating the Perinatal Beta-Cell
Adaptive Response to Early-Life Stressors. Molecular mech-
anisms responsible for impaired beta-cell mass formation
after IUCR or IUPR have come under investigation.
First, it has been proposed that IUCR can result in a
reduction of the embryonic beta-cell progenitor pool leading
to inappropriate postnatal beta-cell formation. Stanger et
al. [108] demonstrated that selective genetic reduction in
the size of PDX-1+ pancreatic progenitors during the fetal
period results in impaired beta-cell formation during the
postnatal period with consequent development of glucose
intoleranceduringadulthood.Consistentwiththis,maternal
food restriction leads to signiﬁcant reduction in PDX-1+
and neurogenin-3+ pancreatic precursors during embryonic
development in rats, diminished postnatal beta-cell forma-
tion, and inability to expand beta-cell mass in response to
pregnancy [47, 94]. The UPI model is also characterized by
a permanent decrease in islet PDX-1 mRNA expression. This
decrease has recently been shown to be due to progressive
epigenetic silencing of the Pdx1 gene locus secondary to
proximal promoter methylation [69, 109], and it may be
responsible for the decreased rate of beta-cell replication
and inappropriate postnatal beta-cell mass development [69,
110].Inthesamewayofthinking,studieshavedemonstrated
that the maintenance of methylated histone H3 Lys4 by
Set7/9, a member of the SET methyltransferase family, is
crucial to Pdx1 activity in beta-cell lines [111–113]. This
led to the hypothesis that Set7/9 may represent a novel
chromatin-modifying protein that functions in part through
its recruitment to target genes by cell-speciﬁc transcription
factors such as Pdx1. Since then, a role of histone methyl
transferases, particularly set7, has also been demonstrated
in the sustained deleterious eﬀects of chronic hyperglycemia
on human microvascular endothelial cells [114]. Such an
epigenetic change could potentially be involved in the
deleterious eﬀect of high glucose upon the fetal pancreas in
the IUED models.
Another mechanism proposed to explain reduced beta-
cell formation after IUCR is related to prenatal glucocor-
ticoid exposure. Administration of either dexamethasone
or carbenoxolone (to inhibit 11 β-hydroxysteroid dehydro-
genase type 2) to normal pregnant rats also causes fetal
growth retardation and the adult oﬀspring are hyperten-
sive and hyperglycemic, with hyperactive hypothalamic-
pituitary-adrenal axis [115]. Maternal undernutrition sig-
niﬁcantly increased both fetal and maternal corticosterone
concentrations in rats [116]. Subsequently, maternal and/or
fetal overexposure to glucocorticoids (via administration of
dexamethasone) impairs both fetal and postnatal beta-cell
f o r m a t i o ni nr o d e n t sa n dn o n h u m a np r i m a t e s[ 94, 117–
119]. Seckl et al. [115] have shown that fetal corticosterone
concentrations are inversely correlated with fetal insulin
content and postnatal beta-cell formation in rats. Evidence
suggests that glucocorticoids can exert a direct eﬀect on8 Experimental Diabetes Research
the developing fetal pancreas via transcriptional modulation
of transcription factors involved in beta-cell formation and
diﬀerentiation [117]. Glucocorticoid receptors are present in
the pancreas during embryonic development of rodents and
humans[117],andglucocorticoidscanbindtothePdx1pro-
moter and thus suppress fetal endocrine cell diﬀerentiation
[117]. Glucocorticoid treatment has been shown to signiﬁ-
cantly reduce fetal expression of key endocrine transcription
factors such as Pdx1 and Pax6 but simultaneously increase
expressionoftranscriptionfactorsthatregulatedevelopment
of the exocrine pancreas [119].
It has also been demonstrated that the UPI or the
low-protein IUPR oﬀspring experience increased oxidative
stress and impaired mitochondrial function [96, 120]. The
mitochondrial dysfunction was not limited to just the beta
cell, as mitochondria from both the liver and skeletal
muscleexhibitdecreasedoxidationofpyruvate,subsequently
leading to the development of features commonly found in
T2D [100, 121]. Also exposure to a Western-style diet before
andduringpregnancy(anIUEOmodel)alterstheredoxstate
as early as preimplantation development, leading to mild
oxidative stress associated with inﬂammation. The ﬁnding
that administration of antioxidants to the dam reverses
oxidative stress and completely prevents the development
of glucose intolerance and increased adiposity in the adult
oﬀspring suggests that oxidative stress plays an important
role in the development of adiposity in this case [122]. Some
studies in the low-protein IUPR model have demonstrated
that oxidative stress is not limited to just mitochondrial
DNAdamage,butalsotogenomicDNA,impactingcell-cycle
regulation and gene expression [123]. While DNA is being
targetedthroughoutbyROS,thereareparticularregionsthat
are known to be more sensitive to ROS-mediated damage,
for example, telomeres. Telomeres comprise GC-rich repeats
and are found at the ends of each chromosome. They are
known to shorten with each cellular division and, hence, can
act as a mitotic clock, registering the number of replicative
divisions to have taken place within the cell. Investigations
using an IUPR model have indeed reported a decrease
in longevity in the oﬀspring [123, 124] accompanied by
reduction in mitochondrial antioxidant defences [96, 125]
and telomere length in islets [125].
Pancreatic islet development has been shown to be inﬂu-
enced by a number of growth factors including the insulin-
like growth factors, IGF-I and IGF-II whose expression in
utero is regulated by nutrient and hormone concentrations.
IUPR modiﬁes expression of both IGF genes in a variety
of fetal tissues. In an IUPR rat model with a decreased
beta-cell mass and beta-cell replication and an increased
rate of beta-cell apoptosis, gene expression for IGF-II but
not IGF-I was found reduced in the fetal pancreas [126].
In a diﬀerent IUPR model with more severe global food
restriction which induced hyperinsulinemia and an increase
in beta-cell mass in their fetuses [90], the fetal phenotype
was unexpectedly associated with an increase in pancreatic
IGF-I expression, islet IGF-1R [91], and IRS-2 [92]. In
the fetal GK/Par rat exposed to mild hyperglycemia during
gestation (a model of IUED), data from our group suggest
that the beta-cell deﬁcit (reduced by more than 50%) starts
as early as fetal age E16 and reﬂects decreased beta-cell
proliferation, a limitation of beta-cell neogenesis from pre-
cursors, and increased apoptosis of both beta cells and their
precursors [86]. Notably, Pdx1 and Neurogenin3 expression
were decreased on E18 but normally expressed on E13
[86]. Defective signalling through the Igf2/Igf1-R pathway
may represent the primary instrumental anomaly since Igf2
and Igf1-R protein expressions are already decreased within
the GK/Par pancreatic rudiment at E13, at a time when
beta-cell mass (ﬁrst wave of beta-cell expansion) is in fact
normal [31]. Low levels of pancreatic Igf2 associated with
beta-cell mass deﬁciency are maintained thereafter within
the fetal pancreas [87]. Crossbreeding protocols between
nondiabetic W and diabetic GK rats showed that, in late
gestation(E18),pancreaticIgf2proteinexpressionwasaslow
in GKmother/GKfather and Wmother/GKfather crosses as
in GKmother/GKfather crosses [87]. These ﬁndings rather
support the hypothesis that the pancreatic Igf2 anomaly in
the GK diabetic model is linked to a genetic determinism.
This view is also consistent with the results of genetic
analyses that linked a locus containing the gene encoding
Igf2 to diabetes in the GK rat [127]. The Igf2 gene is
subjected to paternal genomic imprinting. However, because
the Igf2 expression is similarly aﬀected in fetuses, regardless
of whether the father is W or GK [87], we cannot conclude
with a simple change of Igf2 gene imprinting in the GK rat.
Finally, our understanding of the underlying mech-
anisms for reduced BCM in response to inappropriate
perinatal nutrition is growing rapidly. However, the relative
contribution of the many intrinsic and extrinsic factors
which contribute to the adaptive response of the developing
endocrine pancreas is still to be established.
4. Various Early-LifeStressors:
O n eUl tim at eP r ogram m in g
Inducer—PerinatalHyperglycemia
As abundantly illustrated in animal models, early-life
stressors such as maternal undernutrition, overnutrition,
hypercholesterolemia, corticosteroid therapy, uteroplacental
insuﬃciency,orhypoxiaprogrammetabolicadaptationsthat
initially favour survival but are ultimately detrimental to
adult health. Interestingly, there exists in fact one crucial
commonality between these models with quite diﬀerent
etiologies: in most of the cases, the altered maternal/fetal
metabolism appears to be associated with a diabetogenic
eﬀectintheadultoﬀspringeithermaleorfemale,resultingin
a permanent deﬁciency of the endocrine pancreatic function
(F1). In females, the combination of a latent diabetogenic
tendency (low insulin response) and the metabolic stress
of pregnancy promotes gestational diabetes. F1 gestational
diabetes per se is an inducing factor for impaired glucose
tolerance and gestational diabetes again in the next female
generation (F2).
Finally, the relevant message is that programming of
the endocrine pancreas ultimately originates from hyper-
glycemia experienced during the fetal and/or early postna-
tal life, whatever the etiology of maternal hyperglycemia,Experimental Diabetes Research 9
primary (in F0 diabetic mothers) or secondary (in F1
diabetic mothers issued from F0 mothers exposed to under-
nutrition, UPI, or high glucocorticoid) (Figure 2).
5. Transgenerational Inheritance of
Beta-CellMass Programming
While a large number of animal studies have shown the
eﬀects of undernutrition during foetal/perinatal develop-
ment on the glucose metabolism of oﬀspring (F1) in adult-
hood, several studies have shown that glucose metabolism is
also altered in the oﬀspring (F2) as well as grand oﬀspring
(F3) of fetally malnourished F1 females, even when the F1
and F2 females have been well nourished since weaning [32,
128]( Figure 1, Table 1). With an aim to dissect the relative
parental contributions that lead to F2 oﬀspring outcomes in
thesemodelsofmaternal(F0)undernutrition,itwasrecently
reported that F1 males exhibit moderate hyperglycemia and
IGT with aging and impaired glucose-stimulated insulin
secretion and that all F2 oﬀspring of F1 males or F1 females
develop glucose intolerance [99]. Therefore, intergenera-
tional progression of glucose intolerance can derive from
both the maternal and paternal lines. This is an experimental
proof that transgenerational transmission of IGT may also
occur through the paternal lineage, beside the more widely
acceptedmaternalandgrandmaternalinheritanceofdiabetes
[94, 99, 128, 129].
Conceptually, transgenerational inheritance of disease
risk may be mediated by nongenomic mechanisms, includ-
ing either (1) epigenetic mechanisms [130–133]o r( 2 )
other broader indirect mechanisms associated with parental
physiology [134]. First, alterations in nutrition during
development can alter epigenetic marks, thus regulating
gene expression through DNA methylation and/or histone
modiﬁcations. Interestingly, such epigenetic modiﬁcations
may progress with aging during postnatal life, in association
with metabolic phenotypes, as recently observed at the Pdx1
and GLUT4 loci in UPI rats [109, 135]. If these epigenetic
changesoccurinthegermline,theycanbeinheritedthrough
meiosis [136], thus providing a plausible explanation for
intergenerational eﬀects, transmitted via either maternal or
paternallines.Inaddition,otherindirectbiologicalprocesses
may inﬂuence phenotypes in subsequent generations. For
example,physicalconstraintsmayalterbirthsizethroughthe
maternal lineage: since uterine size is reduced in girls that are
born small and remain short, this may inﬂuence fetal growth
and reduce weight in their progeny [134].
Furthermore, maternal metabolism may also inﬂuence
cross-generational phenotypes [32]. Maternal undernutri-
tion during pregnancy (F0) increases risk for developing
diabetes and obesity in her oﬀspring (F1). When these
high-risk adult F1 females become pregnant, the metabolic
stress of pregnancy may result in hyperglycemia and/or
overt gestational diabetes that may, in turn, contribute
to defective beta-cell mass and increased diabetes risk in
F2 oﬀspring [32]. By this mechanism gestational diabetes
may pass from one generation to the next one. In these
last examples, intergenerational transmission of phenotypes
would occur exclusively through the maternal lineage, as
opposed to the epigenetic mechanisms mentioned above.
Such a scenario is relevant to the GK/Par rat (Figure 3),
since the GK/Par mothers are mildly hyperglycemic through
their gestation and during the suckling period. It oﬀers
a rationale to elucidate several clues: (1) the initiation
of pancreas programming in the F1 oﬀspring of the ﬁrst
founders (F0), since the GK line is issued from intercrosses
between Wistar females and males with borderline IGT but
otherwise normal basal blood glucose level [23]; (2) the
progressionoftheIGTphenotypeuntilastablemilddiabetic
phenotype was reached among the generations n = 30 [23];
(3) the lack of attenuation of the diabetic GK phenotype
overtime (along more than 20 years and 80 generations),
since oﬀspring of GK female/W male crosses were more
hyperglycemic than those of W female/GK male crosses
[89].
6.Epigenetic MechanismsMediating
theDiabetesRiskAssociatedwith
Beta-CellMass Programming
Several lines of evidence indicate that epigenetic modiﬁ-
cation may be a key unifying mechanism mediating risk
associated with a perturbed intrauterine environment. First,
disruption of physiologic responses and functional capacity
as observed in multiple tissues of IUED or IUGR animals
and humans, including muscle, adipose, pancreas, liver,
and CNS may be related to histone modiﬁcation and
DNA methylation, thereby altering related gene expression
[133].
The preimplantation embryo is particularly sensitive to
epigenetic modiﬁcations that might permanently alter the
phenotype in the adult [105, 137]. For example, in the
agouti mouse model, folate supplementation of the maternal
diet at conception increases DNA methylation of the agouti
gene and increases longevity of the oﬀspring [138]. Maternal
protein restriction has been shown to alter the methylation
status of the promoters of the glucocorticoid receptor [97],
PPARα [98], and the angiotensin receptor [139] with parallel
c h a n g e si ng e n ee x p r e s s i o n .M o r er e c e n ts t u d i e sh a v es h o w n
that histone modiﬁcations can also be inﬂuenced by the early
environment. Alterations in histone modiﬁcations have also
been implicated in mediating the eﬀect of caloric restriction
during the second half of pregnancy on the programmed
reduction of GLUT4 expression in the oﬀspring [135]. In
the case of the UPI rat model and the pancreatic tissue,
Stoﬀers and colleagues have reported a progressive reduction
in expression of Pdx1, a key transcription factor regulating
pancreatic development and function [69]. Pdx1 expression
is reduced by 50% in UPI fetuses and by 80% in adult UPI
oﬀspring. Notably, these changes precede the onset of beta-
cell dysfunction, suggesting a primary pathogenic role. Since
the Pdx1 promoter is a target for epigenetic modiﬁcation, as
it contains a conserved CpG islands and is associated with
high levels of histone acetylation. Interestingly, binding of
both acetylated histone H3/H4 and the transcription factor
USF1 was found abolished in UPI fetuses [109]. While there10 Experimental Diabetes Research
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Figure 3: Mechanisms for the installation and intergenerational transmission of programmed beta-cell mass (BCM) disruption in the
GK/Parratmodeloftype2diabetes.MaternalIGT/diabetesduringgestationinducesBCMprogrammingintheﬁrst(F1)andthesubsequent
rat generations. Metabolic modiﬁcations in the pups during the in utero and suckling periods are followed by the onset of pathological
conditions in adulthood (glucose intolerance and type 2 diabetes) and the transmission of programmed endocrine/metabolic capacities to
the next generation. W: Wistar strain.
was methylation at multiple CpGs in UPI adult oﬀspring, no
methylation was detected in UPI neonates, indicating that
methylation was unlikely to explain Pdx1 repression early in
life. Together, these data indicate that progressive silencing
of gene expression is largely initiated by early epigenetic
changes and is maintained thereafter even in the absence of
further experimental insults during postnatal life. UPI also
increases histone acetylation of the PPARγ coactivator PGC-
1 and carnitine-palmitoyltransferase I (CPT1) promoters in
newborn and young rats, and these changes are associated
with increased PGC-1 and CPT1 mRNAs [101]. Finally,
there is now little doubt that epigenetic regulation of gene
expression also occurs in humans as a response to early
nutritionalinsult:arecentstudyhasrevealedthatindividuals
who were exposed to famine in utero during the Dutch
Hunger Winter had altered methylation of the Igf2 gene in
white blood cells in adulthood [140].
7. Implications for Public Health
Although the focus of most studies in the metabolic
programming ﬁeld has been on delineating the eﬀects of
reduced maternal nutrition, there is now a growing interest
in the role of maternal overnutrition in the programming of
diabetes risk. The worldwide prevalence of obesity continues
to increase, in association with an increase in the risk of
metabolic T2D. Indeed, a recent study estimated that the
number of people worldwide with diabetes would increase
from 171 million in 2000 to 366 million by 2030 if the
prevalence of obesity remained constant [141], which has
major implications for public health strategies worldwide
[142]. This global trend to increasing obesity is reﬂected
in the increasing numbers of women who are obese during
pregnancy [143]. Given that the oﬀspring of obese mothers
have an increased risk of developing obesity and T2DExperimental Diabetes Research 11
themselves[144,145],thepotentialimpactoftheintergener-
ational consequences of maternal obesity is of great concern
for public health policy makers.
Moreover, maternal hyperglycemia per se increases the
probability of adolescent obesity and future T2D. To what
extent maternal hyperglycemia is fuelling the global rise in
obesity and T2D is unknown, but its contribution is highly
signiﬁcant. The exact degree of hyperglycemia that has this
eﬀect and the exact timing in pregnancy that hyperglycemia
is impressionable on fetal programming is unknown. The
need to identify and treat all women with gestational
diabetes is very much dependent on us knowing this.
Meanwhile, achieving rigorous glycemic control in women
with diabetic pregnancy has to remain a major therapeutic
goal.
Several interventions (dietary or pharmacological) to
reduce the long-term sequelae of early-life programming
eﬀects have been used in animal models. For example, the
administration of folic acid with a low-protein diet during
pregnancy prevents the altered phenotype and epigenotype
in rat oﬀspring [97], and administration of a diet rich
in methyl donors prevents the transgenerational increase
in obesity in agouti yellow mice [146]. Importantly, the
timingofsuchinterventionscanbecrucial.Examplesinclude
neonatal leptin treatment which reverses the programming
eﬀects of prenatal undernutrition [147]. In the UPI rat
model, epigenetic silencing of the Pdx1 gene can be reversed
during a critical developmental window in the neonatal
period, using trichostatin A which inhibit HDACs [109].
In the same model, exposure to exendin-4 in the neonatal
period reversed the detrimental fetal programming of the
beta-cell mass and prevented the development of diabetes
in adulthood: this was closely related to restoration of pdx1
expression and beta-cell proliferation rate [69]. A GLP-1
or exendin-4 treatment limited to the neonatal prediabetic
period was also shown to delay the installation and limit the
severity of T2D in the GK/Par model [88]. In such context,
it is important to note that GLP1-derived drugs that are cur-
rently used to treat patients with T2D may target chromatin
remodelling. Treating beta cells from the INS1 cell line or
dispersedmouseisletcellswithGLP-1increasedglobalacety-
lation of histone H3 and increased its phosphorylation in a
concentration-dependent manner [148]. Such histone mod-
iﬁcations increased association with the transcription factor
phospho-CREB and with cAMP-response CREB coactivator
2. Taken as a whole, these data may provoke optimism—that
there may be a window for potential postnatal therapeutic
interventions to prevent/modify the “programmed” diabetes
risk.
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